BMO Capital Reiterates Outperform Rating on Biogen (BIIB)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. LVS
7. SAP
8. CSX
9. LRCX
10. MRK

Go back to BMO Capital Reiterates Outperform Rating on Biogen (BIIB)

Leqembi® (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain

August 22, 2024 5:11 AM EDT

FOR GLOBAL MEDIA AND JOURNALISTS OUTSIDE THE EMEA REGION 

In Great Britain, lecanemab is indicated for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease (AD) in adult patients that are apolipoprotein E 4 (ApoE 4)* heterozygotes or non-carriers1

Great Britain becomes the first country in Europe to authorize the medicine, which targets an underlying cause of... More